ArticleFrontiers in veterinary science2026
A novel bovine viral vaccine for reproductive safety and performance in cattle.
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bovine herpesvirus-1 (BoHV-1), the causative agent of infectious bovine rhinotracheitis (IBR), and bovine viral diarrhea virus (BVDV) vaccines are one of the tools that can be used to improve reproductive efficiency, but ordinary modified-live BoHV-1 components can establish latency, impair fertility or cause abortion. This work evaluated the reproductive safety of a gene-deleted BoHV-1 (gE-/tk-) marker strain used alone or within a multivalent vaccine (BoHV-1 gE-/tk-, recombinant BVDV-1 and BVDV-2 E2 protein, modified live bovine respiratory syncytial virus, inactivated parainfluenza-3). Latency and reactivation were examined in 10 seronegative calves vaccinated twice and later treated with dexamethasone, with non-vaccinated calves and virulent BoHV-1 infection included as negative and positive controls, respectively. Conception effects were assessed in four preclinical heifer trials including vaccinated and non-vaccinated control groups, differing in age and vaccination-to-breeding interval, as well as in two gestational safety studies conducted at different trimesters using either the commercial antigen dose (1X) or a 10-fold increase (10X) of the IBR antigen content. A large field trial on four commercial dairies evaluated conception rate and pregnancy loss in vaccinated animals compared with controls. Vaccine virus was not recovered from nasal swabs, trigeminal ganglia, or tonsils after dexamethasone, whereas challenge calves showed typical reactivation and shedding. Across preclinical trials, vaccination did not reduce conception rate. In both 1X and 10X gestation studies, no abortions occurred, and all viable calves were clinically normal and BoHV-1 seronegative at birth. In the field trial, a farm with extensive records demonstrated a conception rate significantly higher in the vaccinated animals after the second dose compared to controls, while similar rates were observed following the other doses. Pregnancy loss did not differ between vaccinated and control animals. These data demonstrate that the gE-/tk- BoHV-1 marker strain, alone or in a multivalent format, does not establish detectable latency or adversely affect fertility or gestational outcome, supporting its reproductive safety in cattle worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.